Centurium Capital-backed CBPO Holdings completed the acquisition of China Biologic Products Holdings for $4.76bn.

Centurium Capital-backed CBPO Holdings, a special purpose acquisition company, agreed to acquire China Biologic Products Holdings, a blood plasma-based biopharmaceutical company, for $4.76bn. The company also announced that it has requested that trading of its shares on the Nasdaq Market be suspended as of the close of trading on April 20, 2021, notifying the SEC of the delisting of the shares on Nasdaq and the deregistration of the company's registered securities.